- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00261222
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
Design: Single-centre
Indication: Malaria caused by Plasmodium falciparum Objectives: To determine and compare the efficacy of AQ treatment in young children with uncomplicated falciparum malaria in the rural and the urban study area of the Centre de Recherche en Santé de Nouna (CRSN).
Population: Children aged 6-59 months with uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C + ≥ 2.000 P. falciparum asexual parasites per µl blood) from the health centre situated in the villages of Bagala, Bourasso and Kemena and from Nouna town hospital outpatient department.
Sample size: N=120
Treatment: All children will receive a total dose of 25 mg/kg oral AQ over a period of three days (first and second day: 10mg/kg, third day: 5mg/kg).
Statistical procedures: The primary analysis parameter is the proportion of clinical failures on day 14. Secondary parameters are the rate of clinical failures on day 28 (with and without PCR correction), the rate of early clinical failures, the rate of late parasitological failures (day 14 and day 28), and the rate of adverse events. Data will be analysed in the overall group of study children and for rural (n=50) and urban (n=50) study children separately.
Study duration and dates: The study will be implemented in September-December 2005.
Study Overview
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Nouna, Burkina Faso, P.O. Box 34
- Centre de Recherche en Santé de Nouna (CRSN)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 6-59 months
- Uncomplicated falciparum malaria (axillary temperature ≥ 37.5°C and ≥ 2.000 P. falciparum asexual parasites per µl blood)
- Written informed consent given by the parents/caretakers
Exclusion Criteria:
- Complicated or severe malaria (repeated vomiting, seizures or other neurological impairment, haemoglobin < 7 g/dl or haematocrit < 21%)
- Any apparent significant disease (e. g. pneumonia, meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition)
- Malaria treatment with western drugs and/or antibiotics with anti malarial potency during last 7 days except chloroquine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Total clinical failure rate on day 14.
|
Clinical failure rate on day 14 in rural study area.
|
Clinical failure rate on day 14 in urban study area.
|
Secondary Outcome Measures
Outcome Measure |
---|
Total clinical failure rate on day 28.
|
Clinical failure rate on day 28 in rural study area.
|
Clinical failure rate on day 28 in urban study area.
|
Total early clinical failure rate.
|
Early clinical failure rate in rural study area.
|
Early clinical failure rate in urban study area.
|
Total late parasitological failure rate on day 14 and 28.
|
Late parasitological failure rate on day 14 and 28 in rural study area.
|
Late parasitological failure rate on day 14 and 28 in urban study area.
|
Incidence of observed and self-reported adverse events over the 28 days observation period
|
Monitoring of concomitant drug intake
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Germain Mandi, MD, Centre de recherche en Santé de nouna
- Study Director: Olaf Mueller, MD, PhD, University of Heidelberg, Germany, Institute of Tropical Medecine and Public Health
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SFB544-A8-AQ2005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Amodiaquine
-
PfizerCompleted
-
London School of Hygiene and Tropical MedicineCompleted
-
Charite University, Berlin, GermanyKintampo Health Research Centre, Ghana; University for Development Studies,...Unknown
-
Swiss Federal Institute of TechnologySwiss National Science Foundation; Swiss Tropical & Public Health InstituteCompleted
-
London School of Hygiene and Tropical MedicineUniversity of NairobiCompletedMalaria, FalciparumKenya
-
PfizerCompleted
-
University of OxfordMahidol University; Mahidol Oxford Tropical Medicine Research UnitTerminatedHealthy | Pharmacokinetic | Drug CombinationThailand
-
Heidelberg UniversityCompleted
-
Bandim Health ProjectCompleted
-
SanofiMedicines for Malaria VentureCompleted